Characteristics and healthcare costs of patients with fibromyalgia syndrome

Pfizer Inc., New York, New York, United States
International Journal of Clinical Practice (Impact Factor: 2.54). 09/2007; 61(9):1498-508. DOI: 10.1111/j.1742-1241.2007.01480.x
Source: PubMed

ABSTRACT To examine the characteristics and healthcare costs of fibromyalgia syndrome (FMS) patients in clinical practice.
Using a US health-insurance database, we identified all patients, aged > or = 18 years, with any healthcare encounters for FMS (ICD-9-CM diagnosis code 729.1) in each year of the 3-year period, 1 July 2002 to 30 June 2005. A comparison group was then constituted, consisting of randomly selected patients without any healthcare encounters for FMS during this 3-year period. Comparison group patients were matched to FMS patients based on age and sex. Characteristics and healthcare costs of FMS patients and comparison group patients were then examined over the 1-year period, 1 July 2004 to 30 June 2005 (the most recent year for which data were available at the time of the study).
The study sample consisted of 33,176 FMS patients and an identical number in the comparison group. Mean age was 46 years, and 75% were women. FMS patients were more likely to have various comorbidities, including painful neuropathies (23% vs. 3% for comparison group), anxiety (5% vs. 1%), and depression (12% vs. 3%) (all p < 0.001); they also were more likely to have used pain-related pharmacotherapy (65% vs. 34% for comparison group; p < 0.001). Mean (SD) total healthcare costs over 12 months were about three times higher among FMS patients [$9573 ($20,135) vs. $3291 ($13,643); p < 0.001]; median costs were fivefold higher ($4247 vs. $822; p < 0.001).
Patients with FMS have comparatively high levels of comorbidities and high levels of healthcare utilization and cost.

Download full-text


Available from: Ariel Berger, Aug 06, 2015
  • Source
    • "In addition to the personal consequences, substantial healthcare costs are accrued. For example, between 2002 and 2005, annual healthcare costs in the US were three times higher in people with FM versus those without FM [2]. Management of FM includes both pharmacologic and nonpharmacologic approaches [3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibromyalgia is a major public health problem affecting an estimated 200 to 400 million people worldwide. The purpose of this study was to use the meta-analytic approach to determine the efficacy and effectiveness of randomized controlled exercise intervention trials (aerobic, strength training, or both) on tender points (TPs) in adults with fibromyalgia. Using random effects models and 95% confidence intervals (CI), a statistically significant reduction in TPs was observed based on per-protocol analyses (8 studies representing 322 participants) but not intention-to-treat analyses (5 studies representing 338 participants) (per-protocol, g, -0.68, 95% CI, -1.16, -0.20; intention-to-treat, g, -0.24, 95% CI, -0.62, 0.15). Changes were equivalent to relative reductions of 10.9% and 6.9%, respectively, for per-protocol and intention-to-treat analyses. It was concluded that exercise is efficacious for reducing TPs in women with FM. However, a need exists for additional well-designed and reported studies on this topic.
    10/2011; 2011:125485. DOI:10.1155/2011/125485
  • Source
    • "j o u r n a l h o m e p a g e : w w w. e l s ev i e r. c o m / l o c a t e / j a d For example, a recent study has found that the majority of patients had nausea, constipation, colicky abdominal pain, orthostatic hypotension, and dizziness (Solano et al., 2009). Besides, psychiatric symptoms such as depressive, anxious and sleep disorders have frequently been associated to FM (Berger et al., 2007; Raphael et al., 2006). The physical and mental distress experienced by FM patients strongly affects quality of life, social and work performances , to the point that FM has been called the " invisible disability " (Sturge-Jacobs, 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibromyalgia is characterized by chronic widespread musculoskeletal pain and higher pain perception in specific anatomic sites called tender points. Fibromyalgia is frequently associated with psychiatric symptoms, like depression and anxiety; indeed some authors have argued about the possibility to classify this syndrome into affective spectrum disorder. Few studies have analyzed the impact of depressive symptoms on pain threshold. This research is aimed at evaluating the prevalence and the clinical correlates of depressive symptoms in fibromyalgic patients, and investigating their impact on pain perception and quality of life. Outpatients between 18 and 75 years with diagnosis of fibromyalgia according to the criteria of the American College of Rheumatology have been included. All subjects have been evaluated with the following rating scales: HAM-D; VAS (to quantify pain); a visual analogical scale to evaluate quality of life; and Paykel's List of Recent Life Events. Thirty subjects have been recruited. Most patients (83.3%) had clinically significant depressive symptoms as indicated by a HAM-D score >7. Depressive symptoms are associated with higher pain perception, worse quality of life and more severe life events. The presence of depressive symptoms is associated with a great impairment in patients with fibromyalgia syndrome: indeed the psychiatric comorbidity lowers pain threshold and worsens the quality of life of our patients. Future studies should be conducted in order to identify the individual factors, e.g. stress or inflammatory processes, which drive the association between depression and higher severity of fibromyalgia syndrome.
    Journal of Affective Disorders 02/2011; 128(3):262-6. DOI:10.1016/j.jad.2010.07.004 · 3.71 Impact Factor
  • Source
    • "Clinically, individuals with FM present with a variety of physical symptoms that include widespread pain, fatigue, sleep disturbance, decrements in physical functioning, and disruptions in psychological functioning (e.g., cognitive difficulties, mood disturbances, and lack of well-being) [8] [38] [70]. FM occurs more frequently in females [71] and is associated with higher than average healthcare utilization [9]. Pharmacological agents, particularly those classified as dual reuptake inhibitors and anticonvulsants possess the strongest evidence for efficacy in FM [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Both pharmacological and non-pharmacological interventions have demonstrated efficacy in the management of fibromyalgia (FM). Non-pharmacological interventions however are far less likely to be used in clinical settings, in part due to limited access. This manuscript presents the findings of a randomized controlled trail of an Internet-based exercise and behavioral self-management program for FM designed for use in the context of a routine clinical care. 118 individuals with FM were randomly assigned to either (a) standard care or (b) standard care plus access to a Web-Enhanced Behavioral Self-Management program (WEB-SM) grounded in cognitive and behavioral pain management principles. Individuals were assessed at baseline and again at 6 months for primary endpoints: reduction of pain and an improvement in physical functioning. Secondary outcomes included fatigue, sleep, anxiety and depressive symptoms, and a patient global impression of improvement. Individuals assigned to the WEB-SM condition reported significantly greater improvement in pain, physical functioning, and overall global improvement. Exercise and relaxation techniques were the most commonly used skills throughout the 6 month period. A no-contact, Internet-based, self-management intervention demonstrated efficacy on key outcomes for FM. While not everyone is expected to benefit from this approach, this study demonstrated that non-pharmacological interventions can be efficiently integrated into routine clinical practice with positive outcomes.
    Pain 12/2010; 151(3):694-702. DOI:10.1016/j.pain.2010.08.034 · 5.84 Impact Factor
Show more